---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-26-008771"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:29:47.466762+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Tonix reports preclinical data for TNX-1700 and TNX-4700 at AACR 2026

## Summary
- TNX-1700 reversed aging-associated gastric inflammation and attenuated tumor progression in aged mouse model.
- TNX-1700 showed dose-independent linear PK in non-human primates and transgenic mice; no significant weight loss.
- TNX-4700 anti-BTLA mAbs demonstrated potent, high-affinity binding and functional antagonism in vitro.
- Three TNX-4700 antagonists had reduced FcgRI binding and no FcgRIIB binding, potentially lowering FcR-dependent toxicities.

## SEC filing metadata
- accession: 0001999371-26-008771
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937126008771/0001999371-26-008771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937126008771/tnxp_8k-042226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-26-008771
- JSON: https://secwatch.observer/filing/0001999371-26-008771.json
- Plain text: https://secwatch.observer/filing/0001999371-26-008771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.